Bivalent RSV pre‑F Vaccine Dramatically Reduces RSV‑Associated Hospitalisations and Chronic‑Disease Exacerbations in Adults Aged 75–79 Years
Posted inInfectious Diseases news Respiratory

Bivalent RSV pre‑F Vaccine Dramatically Reduces RSV‑Associated Hospitalisations and Chronic‑Disease Exacerbations in Adults Aged 75–79 Years

In a multicentre test‑negative study of 1006 adults aged 75–79 in England, a bivalent RSV pre‑F vaccine reduced RSV‑associated hospitalisation by 82% overall and protected against severe disease and exacerbations of chronic heart and lung disease, including in immunosuppressed patients.
Brand-Specific Influenza Vaccine Effectiveness in Nordic Older Adults: Insights from the 2024-2025 Season Registry-Based Target Trial Emulation
Posted inClinical Updates Infectious Diseases news Public Health Respiratory

Brand-Specific Influenza Vaccine Effectiveness in Nordic Older Adults: Insights from the 2024-2025 Season Registry-Based Target Trial Emulation

This comprehensive review synthesizes recent evidence on brand-specific influenza vaccine effectiveness (VE) among adults aged ≥65 in Denmark, Finland, and Sweden during the 2024-2025 season, underscoring heterogeneous VE profiles and the clinical impact of high-dose adjuvanted vaccines.
DAGO2 (daunorubicin+cytarabine+fractionated gemtuzumab) outperforms CPX‑351 in older adults with non‑adverse‑risk AML: insights from NCRI AML18
Posted inHematology-Oncology news

DAGO2 (daunorubicin+cytarabine+fractionated gemtuzumab) outperforms CPX‑351 in older adults with non‑adverse‑risk AML: insights from NCRI AML18

In NCRI AML18 (n=439, median age 68), DAGO2 produced higher early CR/MRD‑negative rates and superior 3‑year EFS and OS versus CPX‑351 in older adults without adverse‑risk cytogenetics; survival differences persisted across key subgroups including NPM1 and FLT3 mutations.